Edition:
United Kingdom

NuCana PLC (NCNA.OQ)

NCNA.OQ on NASDAQ Stock Exchange Global Select Market

16.20USD
18 Dec 2018
Change (% chg)

-- (--)
Prev Close
$16.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
9,417
52-wk High
$30.80
52-wk Low
$9.48

Latest Key Developments (Source: Significant Developments)

NuCana Reports Q3 2018 Financial Results & Provides Business Update
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - NuCana PLC ::NUCANA REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE GBP 0.08.Q3 EARNINGS PER SHARE ESTIMATE GBP -0.22 -- REFINITIV IBES DATA.NUCANA - INITIATION OF PHASE III STUDY OF ACELARIN IN FRONT-LINE ADVANCED BILIARY TRACT CANCER AND PHASE I STUDY OF NUC-7738 EXPECTED BY END OF 2018.  Full Article

NuCana Q2 Loss Per Share GBP 0.04
Tuesday, 28 Aug 2018 

Aug 28 (Reuters) - NuCana PLC ::NUCANA REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 LOSS PER SHARE GBP 0.04.Q2 EARNINGS PER SHARE VIEW GBP -0.20 -- THOMSON REUTERS I/B/E/S.AS OF JUNE 30, 2018, NUCANA HAD CASH AND CASH EQUIVALENTS OF £81.5 MILLION COMPARED TO £81.3 MILLION AS OF MARCH 31, 2018.  Full Article

Nucana Announces Promising Clinical Data On Nuc-1031 As Front-Line Treatment Of Advanced Biliary Tract Cancer
Friday, 19 Jan 2018 

Jan 19 (Reuters) - Nucana Plc ::NUCANA ANNOUNCES PROMISING CLINICAL DATA AT ASCO GI ON NUC-1031 (ACELARIN®) AS FRONT-LINE TREATMENT OF ADVANCED BILIARY TRACT CANCER.NUCANA SAYS COMBINATION OF ACELARIN AND CISPLATIN WAS WELL-TOLERATED WITH NO UNEXPECTED ADVERSE EVENTS AND NO DOSE-LIMITING TOXICITIES.NUCANA PLC - IN TRIAL, 2 OF 8 PATIENTS RECEIVED ONLY ONE CYCLE OR LESS OF THERAPY DUE TO COMPLICATIONS UNRELATED TO EITHER ACELARIN OR CISPLATIN.NUCANA SAYS PLAN TO INITIATE PIVOTAL STUDY OF ACELARIN AND CISPLATIN IN FRONT-LINE ADVANCED BILIARY TRACT CANCER IN 2018.NUCANA PLC - ANALYSIS OF PHASE 1B STUDY SHOWED ACELARIN, WHEN COMBINED WITH CISPLATIN WAS WELL-TOLERATED IN FRONT-LINE ADVANCED BILIARY TRACT CANCER.NUCANA-STUDY SHOWED ACELARIN, WHEN COMBINED WITH CISPLATIN, ACHIEVED HIGH RESPONSE RATES, WAS WELL-TOLERATED IN FRONT-LINE ADVANCED BILIARY TRACT CANCER.  Full Article

NuCana Plc prices initial public offering of 6.7 mln American Depositary Shares at $15 per ADS
Thursday, 28 Sep 2017 

Sept 27 (Reuters) - Nucana Plc - :NuCana Plc announces pricing of initial public offering.Pricing of initial public offering of 6.7 million American Depositary Shares at price of $15 per ADS, for total gross proceeds of about $100 million.  Full Article